"The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States.
Biological products are generally derived from a living organism. They can come from many sources, in"...
Duraclon is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see Clinical Trials ).
The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS).
DOSAGE AND ADMINISTRATION
The recommended starting dose of Duraclon for continuous epidural infusion is 30 mcg/hr. Although dosage may be titrated up or down depending on pain relief and occurrence of adverse events, experience with dosage rates above 40 mcg/hr is limited.
Familiarization with the continuous epidural infusion device is essential. Patients receiving epidural clonidine from a continuous infusion device should be closely monitored for the first few days to assess their response.
The 500 mcg/mL (0.5 mg/mL) strength product must be diluted prior to use in 0.9% Sodium Chloride for Injection, U.S.P., to a final concentration of 100 mcg/mL:
|Volume of Duraclon 500 mcg/mL||Volume of 0.9% Sodium Chloride for Injection, U.S.P.||Resulting Final Duraclon Concentration (100 mcg/mL)|
|1 mL||4 mL||500 mcg/5 mL|
|2 mL||8 mL||1000 mcg/10 mL|
|3 mL||12 mL||1500 mcg/15 mL|
|4 mL||16 mL||2000 mcg/20 mL|
|5 mL||20 mL||2500 mcg/25 mL|
|6 mL||24 mL||3000 mcg/30 mL|
|7 mL||28 mL||3500 mcg/35 mL|
|8 mL||32 mL||4000 mcg/40 mL|
|9 mL||36 mL||4500 mcg/45 mL|
|10 mL||40 mL||5000 mcg/50 mL|
Dosage should be adjusted according to the degree of renal impairment, and patients should be carefully monitored. Since only a minimal amount of clonidine is removed during routine hemodialysis, there is no need to give supplemental clonidine following dialysis.
Duraclon must not be used with a preservative.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
NDC 67457-218-10, 100 mcg/mL solution in 10 mL vials, packaged individually.
NDC 67457-219-10, 500 mcg/mL solution in 10 mL vials, packaged individually.
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Preservative Free. Discard unused portion.
Manufactured for: Mylan Institutional LLC, Rockford, IL 61103 U.S.A. Manufactured by: Mylan Institutional, Galway, Ireland. Revised: Jun 2012This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 8/29/2016
Additional Duraclon Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.